Last updated: December 31, 2024
Introduction to Eliquis
Eliquis, also known as apixaban, is a potent anticoagulant developed jointly by Bristol-Myers Squibb and Pfizer. It is used to prevent and treat various thromboembolic conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Here’s a comprehensive analysis of the market and sales projections for Eliquis.
Market Size and Forecast
The Eliquis market has been experiencing significant growth. As of 2023, the market size was valued at USD 31.04 billion and is projected to reach USD 75.53 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 9.3% during the forecast period of 2024 to 2031[1].
Key Growth Drivers
Growing Awareness and Diagnoses
The increasing awareness of atrial fibrillation and other thromboembolic conditions is leading to more diagnoses, thereby expanding the patient population that may be prescribed Eliquis[1].
Healthcare Expenditure and Access
Rising healthcare expenditures and the increasing availability of medications in various markets have facilitated greater access to Eliquis. This trend is particularly evident in regions with robust healthcare systems[1].
Market Exclusivity and Patent Protection
The patent protection of Eliquis limits generic competition, allowing Bristol-Myers Squibb and Pfizer to sustain revenue generation. However, this protection is set to expire by 2028, which could impact future sales[2].
Partnerships and Marketing Strategies
Effective marketing strategies and partnerships between pharmaceutical companies and healthcare providers have enhanced the visibility and market penetration of Eliquis. These collaborations are crucial for maintaining market share[1].
Expansion to New Markets
The introduction of Eliquis in emerging markets with growing healthcare infrastructure is driving market growth. Countries like China and India are witnessing a significant increase in demand as their healthcare systems evolve[1].
Sales Performance
Recent Sales Figures
In the third quarter of 2024, Eliquis booked $3 billion in sales, an 11% increase from the year-ago period. This performance exceeded analyst expectations, which were set at $2.84 billion[2][4].
Historical Sales Trend
Since its marketing, Eliquis has shown a steady upward trend in sales. In 2015, its global sales were $1.86 billion, which surged to $10.76 billion in 2021 and further to $11.789 billion in 2022, representing a year-on-year growth of 10% in 2022[5].
Market Segmentation
End-User Segmentation
The Eliquis market is segmented by end-users, including hospitals, outpatient clinics, and pharmacies. Hospitals are significant end-users, administering Eliquis for acute care settings, while outpatient clinics provide a continuum of care for patients managing chronic conditions[1].
Geographic Segmentation
Geographically, the market is diverse, with Europe showing robust adoption rates due to national health systems prioritizing cardiovascular treatments. The Asia-Pacific region, particularly countries like China and India, presents a rapidly growing opportunity. However, the Middle East and Africa face challenges such as limited healthcare resources and lower awareness levels[1].
Challenges and Restraints
Generic Competition
The expiration of patent protection for Eliquis by 2028 may lead to the availability of generic alternatives, significantly impacting its market share and pricing[2].
Regulatory Challenges
The approval of drugs in the anticoagulant class involves rigorous regulatory scrutiny. Any delays or challenges in obtaining approval for new formulations or indications can restrain market growth[1].
Adverse Effects and Safety Concerns
The risk of side effects, such as bleeding complications, may lead to patient reluctance and could hinder the drug’s adoption among healthcare providers[1].
High Cost
Eliquis is relatively expensive compared to some traditional anticoagulants, which may limit its accessibility, particularly in regions with less healthcare funding or among uninsured patients[1].
Market Saturation
The anticoagulant market is becoming increasingly crowded, which can dilute Eliquis’s market share and lead to price competition. Emerging novel therapeutics with better safety profiles or dosing convenience may also pose a competitive threat[1].
Future Outlook
Impact of Price Adjustments
Sales of Eliquis could be affected in 2026 when a new price for the drug goes into effect for certain Medicare patients following negotiations with the federal government, a provision of the Inflation Reduction Act[2].
Pipeline and New Therapies
Bristol-Myers Squibb is focusing on its pipeline, including new therapies like Cobenfy, which has multibillion-dollar potential. However, the launch of these new drugs is expected to be a slow build, and their impact on Eliquis sales will be monitored closely[4].
Key Takeaways
- Market Growth: Eliquis is projected to reach a market size of USD 75.53 billion by 2031, growing at a CAGR of 9.3%.
- Sales Performance: Recent sales figures show an 11% increase year-over-year, exceeding analyst expectations.
- Growth Drivers: Increasing awareness, healthcare expenditure, market exclusivity, and expansion into new markets are key drivers.
- Challenges: Generic competition, regulatory challenges, adverse effects, high cost, and market saturation are significant restraints.
- Future Outlook: Price adjustments and the introduction of new therapies will impact future sales.
FAQs
Q: What is the projected market size of Eliquis by 2031?
A: The Eliquis market is projected to reach USD 75.53 billion by 2031[1].
Q: What are the main growth drivers for the Eliquis market?
A: The main growth drivers include growing awareness of thromboembolic conditions, rising healthcare expenditures, market exclusivity, and expansion into new markets[1].
Q: When is the patent protection for Eliquis set to expire?
A: The patent protection for Eliquis is set to expire by 2028[2].
Q: How has the sales performance of Eliquis been in recent quarters?
A: In the third quarter of 2024, Eliquis booked $3 billion in sales, an 11% increase from the year-ago period[2][4].
Q: What are the potential challenges facing the Eliquis market?
A: Challenges include generic competition, regulatory scrutiny, adverse effects, high cost, and market saturation[1].
Sources
- Verified Market Research - Eliquis Market Size, Share, Scope, Trends, Growth & Forecast
- NBC Philadelphia - Bristol Myers Squibb tops earnings estimates and hikes outlook helped by Eliquis and new drugs
- NBC Connecticut - Bristol Myers Squibb tops earnings estimates and hikes outlook helped by Eliquis and new drugs
- BioSpace - BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs
- Biopharma PEG - Top 10 Projected Best-Selling Drugs in 2024
